US FDA Sets Convalescent Plasma Access Recommendations For Coronavirus Patients

 
• By Derrick Gingery

The agency prefers traditional clinical trials be used, but will also allow expanded access or single-patient emergency INDs for the potential coronavirus treatments.

Coronavirus
The US FDA Center for Biologics Evaluation and Research prefers that convalescent plasma treatments for coronavirus be studied in traditional clinical trials. • Source: Shutterstock

More from US FDA

More from Agency Leadership